Fracture Risk in Men With Congestive Heart Failure : Risk Reduction With Spironolactone

• Published in: Journal of the American College of Cardiology Vol. 52; no. 2; pp. 135 - 138
• Main Authors: CARBONE, Laura D, CROSS, Jessica D, DISHMON, Dwight A, NESHEIWAT, Joseph P, HAJJAR, Mohammad A, CHISHTI, Waqas A, NASSER, Wael, KHAN, Mehwish, WOMACK, Catherine R, CHO, Tara, HASKIN, Ashley R, WEBER, Karl T, RAZA, Syed H, BUSH, Andrew J, SEPANSKI, Robert J, DHAWAN, Saurabh, KHAN, Bilal Q, GUPTA, Malini, AHMAD, Khurram, KHOUZAM, Rami N
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Science 08.07.2008; Elsevier Limited
• Subjects: Aged; Biological and medical sciences; Bone density; Cardiology; Cardiology. Vascular system; Drug therapy; Fractures; Fractures, Bone - etiology; Heart; Heart Failure - complications; Heart Failure - drug therapy; Heart failure, cardiogenic pulmonary edema, cardiac enlargement; Humans; Injuries of the limb. Injuries of the spine; Male; Medical sciences; Middle Aged; Mineralocorticoid Receptor Antagonists - therapeutic use; Older people; Retrospective Studies; Spironolactone - therapeutic use; Studies; Traumas. Diseases due to physical agents; Human; Heart failure; Diseases of the osteoarticular system; Cardiovascular disease; Risk; Fracture; Trauma; Reduction; Spironolactone; Heart disease; Risk factor; Circulatory system; Cardiology

The purpose of this study was to determine whether spironolactone use is associated with fractures in men with congestive heart failure (CHF). In rats with aldosteronism, spironolactone preserves skeletal strength. However, in humans, the relationship of spironolactone to fractures is not known. The...